

*For Immediate Release:
October 27, 2004
Cambridge, MA*

*Contact:
Bill Hayden, Senior Vice President
514-895-2455
bill@coalesix.com*

Coalesix Incorporated Formed To Speed Up Drug Discovery

(October 27, 2004, Cambridge, MA) -- In what will soon trigger an increase in overall pharmaceutical productivity, Coalesix Inc. was incorporated today in Delaware. The company will focus on the further development and commercialization of the drug discovery technology platform developed by Icosystem Corporation.

Key leadership of Coalesix includes President and CEO Paul Edwards and Vice President for Technology Dr. Ihsan Ecemis. Both men have been deeply involved with Icosystem's technology platform since its inception as a proof-of-concept project conducted in collaboration with a major pharmaceutical company.

Coalesix is in the process of seeking its initial funding, including discussions with a number of strategic, individual and institutional investors. The funding round is expected to close by the end of the year.

Headquartered in Cambridge, MA, Coalesix focuses on the development and commercialization of technology to improve the efficiency of drug discovery through the use of its *Mobius* Candidate Design Environment (CDE). *Mobius* offers drug discovery organization the ability to maximize the return on all of their Lead optimization efforts and resources while at the same time helping overcome the lead-to-candidate bottleneck. The *Mobius* CDE fosters interactions between computational and medicinal chemistry to produce a novel approach to address the challenges of Lead Optimization in order to enable faster identification of more potential drug candidates.

More information on Coalesix and the *Mobius* CDE can be obtained by contacting Bill Hayden, Senior Vice President, at 514-895-2455 or bill@coalesix.com